Panagora Asset Management Inc. Decreases Position in Humana Inc (NYSE:HUM)

Panagora Asset Management Inc. decreased its holdings in shares of Humana Inc (NYSE:HUM) by 89.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,681 shares of the insurance provider’s stock after selling 39,950 shares during the quarter. Panagora Asset Management Inc.’s holdings in Humana were worth $1,242,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of HUM. Geode Capital Management LLC lifted its stake in Humana by 8.3% in the fourth quarter. Geode Capital Management LLC now owns 1,773,576 shares of the insurance provider’s stock valued at $507,198,000 after buying an additional 135,776 shares during the last quarter. First Allied Advisory Services Inc. lifted its stake in Humana by 7.8% in the first quarter. First Allied Advisory Services Inc. now owns 5,105 shares of the insurance provider’s stock valued at $1,365,000 after buying an additional 369 shares during the last quarter. Toronto Dominion Bank lifted its stake in Humana by 15.2% in the first quarter. Toronto Dominion Bank now owns 94,501 shares of the insurance provider’s stock valued at $25,131,000 after buying an additional 12,502 shares during the last quarter. CIBC Asset Management Inc lifted its stake in Humana by 7.0% in the first quarter. CIBC Asset Management Inc now owns 16,627 shares of the insurance provider’s stock valued at $4,423,000 after buying an additional 1,085 shares during the last quarter. Finally, Moors & Cabot Inc. lifted its stake in Humana by 77.6% in the first quarter. Moors & Cabot Inc. now owns 1,318 shares of the insurance provider’s stock valued at $350,000 after buying an additional 576 shares during the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

A number of equities research analysts have weighed in on HUM shares. Deutsche Bank started coverage on Humana in a research note on Thursday. They issued a “hold” rating for the company. JPMorgan Chase & Co. boosted their price objective on Humana from $288.00 to $322.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. UBS Group boosted their price objective on Humana from $266.00 to $317.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. Morgan Stanley boosted their price objective on Humana from $315.00 to $342.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Finally, Piper Jaffray Companies boosted their price objective on Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. Humana presently has an average rating of “Buy” and an average target price of $341.95.

Shares of NYSE:HUM traded down $1.33 during trading on Thursday, reaching $275.48. The company had a trading volume of 334,388 shares, compared to its average volume of 1,267,515. The firm has a market capitalization of $37.24 billion, a price-to-earnings ratio of 18.93, a price-to-earnings-growth ratio of 1.19 and a beta of 0.84. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75. The stock’s fifty day moving average price is $287.14 and its 200 day moving average price is $269.38. Humana Inc has a fifty-two week low of $225.65 and a fifty-two week high of $355.88.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.24 by $0.81. The business had revenue of $16.25 billion for the quarter, compared to analyst estimates of $15.88 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.96 earnings per share. On average, equities analysts anticipate that Humana Inc will post 17.63 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date is Friday, September 27th. Humana’s payout ratio is currently 15.12%.

In other news, insider Brian P. Leclaire sold 7,239 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total value of $2,097,138.30. Following the transaction, the insider now owns 12,994 shares of the company’s stock, valued at $3,764,361.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.54% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading: What are the disadvantages of after-hours trading?

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.